Core Viewpoint - The board of directors of China People's Insurance Group Co., Ltd. convened a meeting to discuss and approve various resolutions, including compensation plans for executives and the appointment of a new chief compliance officer [1][2][5][8]. Group 1: Meeting Overview - The fifth board of directors' fourteenth meeting was held on December 30, 2025, in Beijing, with all 11 directors present, ensuring the meeting's legality and effectiveness [1]. - The meeting was chaired by Chairman Ding Xiangqun and included attendance from supervisory board members and senior management [1]. Group 2: Compensation Resolutions - The board approved the compensation settlement plan for the group’s executives for the year 2024, which had been reviewed and approved by the remuneration committee prior to the meeting [2]. - A similar compensation settlement plan for the board members and supervisors for 2024 was also approved and will be submitted for shareholder review [5]. Group 3: Appointments and Policy Approvals - The board approved the appointment of Mr. Bai Feipeng as the company's legal director, chief compliance officer, and chief risk officer, with independent directors expressing their agreement [8][9]. - The board also approved the establishment of interim management measures for consumer rights protection and the revision of the consolidated management measures [11][12]. Group 4: Reports and Audits - The meeting included reports on the special audit results of the solvency risk management system for 2025 and various research reports on audit committee mechanisms and risk management [12].

Group 1 - China People's Health Insurance Co., Ltd. (referred to as "Puhua Health") has invested 200 million yuan to establish Puhua Health Management Co., Ltd., holding a 100% stake [1] - The newly established company will focus on health consulting services, medical device sales and rentals, digital technology services, artificial intelligence application software development, and sales of wearable smart devices [1] - In September 2025, the National Financial Supervision and Administration Bureau approved the establishment of a specialized health management company by Puhua Health [2] Group 2 - Puhua Health aims to enhance the integration of health insurance and health management, transitioning from a traditional fee-for-service model to a managed care model [2] - The company plans to improve its health management service capabilities and provide a comprehensive health care protection service system that includes medical, pharmaceutical, rehabilitation, and insurance services [2] - This initiative is expected to promote innovation in health insurance products and meet diverse health needs while reducing disease claim costs [2]

Core Insights - The 2026 Maoming Marathon, sponsored by China People's Insurance, is set to take place on January 18, 2026, emphasizing the theme of "Mountain and Sea" [22][23]. - The event aims to create a collective declaration of persistence and breakthrough, welcoming participants for both speed and scenic enjoyment [22]. Event Overview - The marathon is branded as not just a running event but an immersive experience that captures the charm of Maoming [22]. - Participants are encouraged to document their experiences through photos and writings, contributing to the collective memory of the event [22]. Sponsorship and Partnerships - China People's Insurance is the main sponsor of the marathon, highlighting its commitment to community engagement and health promotion [24][25]. - The event has various partners, including Maoming Cultural Tourism Development Co., Ltd and Guangdong Sunion Chemical & Plastic Co., Ltd, indicating a collaborative effort to enhance the event's profile [26][32].

白飞鹏，52岁，现为中国人保发法律合规部总经理，高级经济师。白飞鹏曾任人保财险法律部副总经 理，内蒙古自治区分公司副总经理；中国人保法律合规部副总经理。白飞鹏亦兼任中国保险学会法律专 业委员会委员，中国保险资产管理业协会法律合规专业委员会副主任委员，中国保险行业协会法律合规 专业委员会副主任委员，中国人保公益慈善基金会理事。白飞鹏拥有清华大学法学博士学位。 12月30日，中国人保（601319）发布公告称，该公司审议通过了关于聘任白飞鹏为公司法律总监、首席 合规官、首席风险官的议案。 ...

Core Viewpoint - China Pacific Insurance announced the approval of several proposals, including the compensation settlement plan for the group's responsible persons and other senior management for the year 2024 [1] Group 1 - The fifth board of directors of China Pacific Insurance held its 14th meeting to review and approve the compensation settlement plan [1]

Group 1 - The company announced that its 14th meeting of the 5th Board of Directors will be held on December 30, 2025, at the China Pacific Insurance Building in Beijing [1][3] - The meeting approved the appointment of Mr. Bai Feipeng as the company's General Counsel, Chief Compliance Officer, and Chief Risk Officer, with prior review by the Board's Nomination and Compensation Committee [1][3] - Mr. Bai Feipeng, aged 52, is currently the General Manager of the Legal Compliance Department and holds a senior economist title [1][3] Group 2 - Mr. Bai has previously served as the Deputy General Manager of the Legal Department at PICC Property and Casualty and as the Deputy General Manager of the Inner Mongolia Branch [1][3] - He is also a member of the Legal Professional Committee of the China Insurance Society and serves as the Deputy Director of the Legal Compliance Professional Committee of the China Insurance Asset Management Association [1][3] - Mr. Bai holds a Ph.D. in Law from Tsinghua University [1][3]

原标题：斥资2亿，人保健康成立一家全资子公司：总裁邵利铎兼任董事长！"AI+大健康"赛道火热， 头部险企与互联网大厂同台竞技… 来源：险企高参 人保健康正在为构建"保险+健康服务+科技"生态厉兵秣马。 作为国内首家专业健康保险公司，人保健康已积累了很多生态基础，截至2025年三季度末，人保健康已 拥有400余人的专业健康管理队伍、63个企业联合医务室、31个健康管理中心，以及760款标准化健康管 理产品。并且构建起医疗服务网络——5971家合作医院、22.5万家药店、1678家DTP药房，全年创新药 械支付额超15亿元，健康管理服务累计惠及超1亿人次。此外，该司2024年健康管理服务收入总规模突 破5亿元。 在构建健康生态的同时，保险主业亦未曾拉下。截至2025年前三季度，人保健康险的保险服务收入达 232.38亿元，同比增长12.9%；保险服务费用140.51亿元，同比增长10.4%；保险业务收入达506.02亿 元，同比增长15.1%；净利润为78.56亿元，同比增长41%。 按原保险保费收入分类来看，2025年前三季度，人保健康的新单保费规模达375.24亿元，同比增长 16.1%，其中长期保障型业务成 ...

Investment Rating - The report maintains an "Accumulate" rating for the insurance sector [1]. Core Insights - The report discusses the evolution of participating insurance in China, highlighting its significance in a low-interest-rate environment and the shift towards floating yield products, which are gaining traction among domestic investors [2][6]. Summary by Sections 1. What is Participating Insurance? - Participating insurance is a type of insurance that combines protection and investment, allowing policyholders to share in the insurer's surplus [12]. - The operational mechanism involves sharing profits derived from better-than-expected performance, with a minimum of 70% of the surplus distributed to policyholders [6][15]. 2. Historical Development of Participating Insurance in Mainland China - The development of participating insurance has seen significant fluctuations influenced by policy and market factors, with its market share peaking at 75% in 2010 before declining due to market reforms [6][45]. - Since 2024, regulatory policies have encouraged the development of floating yield products, marking a consensus in the industry towards transitioning to participating insurance [6][45]. 3. Current Transition of Participating Insurance - The report anticipates that the proportion of participating insurance will continue to rise, with over 50% of new policies in the first half of 2025 being participating insurance [6][45]. - The transition is expected to alleviate pressure from interest rate losses and enhance the reliability of the insurance sector's embedded value (EV) [6][45]. 4. International Experience - In mature markets, floating yield products dominate, with Hong Kong's participating insurance being a core component, accounting for 85% of new premiums in 2024 [2][6]. - The report suggests that the characteristics of participating insurance in Hong Kong, such as multi-currency support and a design of low guarantees with high floating returns, could serve as a model for the mainland market [2][6]. 5. Key Metrics for Evaluating Participating Insurance - The report outlines four key indicators for assessing the performance of participating insurance: 1. **Guaranteed Rate**: Currently set at 1.75%, which is lower than traditional insurance [23]. 2. **Demonstration Rate**: Reflects expected returns, with current rates around 3.5% to 4% [24]. 3. **Actual Yield**: The industry average is capped at 3.2%, with some companies exceeding this limit [27]. 4. **Dividend Realization Rate**: Increased by 11 percentage points to 62% in 2024, indicating improved management and expectation guidance [29].

本公告乃中國人民保險集團股份有限公司根據《香港聯合交易所有限公司證券上市規則》 第13.10B條的披露義務而作出。 茲載列該公告如下，僅供參閱。 承董事會命 。 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 （於中華人民共和國註冊成立之股份有限公司） （股份代號：1339） 海外監管公告 董事长 中國北京，二零二五年十二月三十日 於本公告日，公司執行董事為丁向群女士、趙鵬先生及肖建友先生，非執行董事 為徐向先生、王少群先生、喻強先生及宋洪軍先生，獨立非執行董事為邵善波先 生、徐麗娜女士、王鵬程先生及高平陽先生。 证券代码：601319 证券简称：中国人保 公告编号：临2025-042 中国人民保险集团股份有限公司 第五届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 丁向群 中國人民保險集團股份有限公司 本公司第五届董事会第十四次会议（以 ...

证券代码：601319 证券简称：中国人保 公告编号：临2025-042 经与会董事审议并表决，形成以下会议决议： 一、审议通过了《关于集团公司负责人和其他高级管理人员2024 年度薪酬清算方案的议案》 本议案已经董事会提名薪酬委员会事前审议通过。 独立董事对该项议案发表了同意的独立意见。 1 表决情况请见本公告附件 1。 薪酬清算表请见本公告附件 2。 二、审议通过了《关于集团公司董事与监事2024年度薪酬清算方 案的议案》，并同意提交股东会审议。 中国人民保险集团股份有限公司 第五届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 本公司第五届董事会第十四次会议（以下简称"会议"）的通知 和材料于 2025 年 12 月 3 日以书面方式通知全体董事，会议于 2025 年 12 月 30 日在北京市西城区西长安街 88 号中国人保大厦以现场会 议方式召开。会议由丁向群董事长主持。会议应出席董事 11 名，实 际出席董事 11 名。监事会成员及部分高级管理层成员列席了会议。 会议的召开符合《中华人 ...